Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is:
To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against Candida glabrata with varying degrees of caspofungin susceptibilities.
This investigation will provide clinicians information supporting the use of caspofungin and micafungin in situations where Candida strains may be a cause of infection.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins in Patients With Presumptive Candidemia|
- Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) [ Time Frame: Pre-treatment, 1.5 hour (h), 12 h and 24 h after receiving the drug ]
Serum cidal activity of serum collected at different timepoints from the patients will be tested against various Candida isolates and the ex-vivo effect reported as log inhibition (logrithmic measurement of the decrease in microbiological growth).
These Candida isolates had a range of minimum inhibitory concentrations (MIC) to Caspofungin (C) and Micafungin (M).
|Study Start Date:||December 2008|
|Study Completion Date:||May 2010|
|Primary Completion Date:||May 2010 (Final data collection date for primary outcome measure)|
Active Comparator: micafungin 100
Patients receive Micafungin 100 mg qd
100 mg qd by slow IV infusion for 24 h
Other Name: Micamine
Active Comparator: micafungin 200
Patients receive 200 mg Micafungin qd
200 mg qd by slow IV infusion for 24 h
Other Name: Micamine
Active Comparator: Caspofungin
Patients receive caspofungin 70 mg LD followed by 50 mg qd
70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
Other Name: Cancidas
Patients - Adult patients with presumptive candidemia. Patients with severe neutropenia (<500) APACHE II scores > 20, or significant liver disease will be excluded. All will give written informed consent (Pappas et al. CID. Oct 1, 2007).
Drugs - Patients will receive either CFG: 70 mg loading dose (LD) followed by 50 mg once daily (qd) (8 patients), MFG: 100 mg qd (8 patients) or MFG: 200 mg qd (8 patients). All agents will be given by slow IV infusion (MFG will be supplied by Astellas).
Sera - Blood samples will be collected at the end of the infusion (peak) and at 12 h and 24 h (trough) after the beginning of an infusion (day 3-4).
Each patients sera will be tested (MIC and cidal activity) against their own Candida isolate (if isolated). In addition, recent clinical isolates of C. glabrata will also be tested against patient sera (time-kill) to verify previous in vitro and animal PD studies (Cota. AAC. Nov. 2006; Wiederhold. AAC. May 2007).
- Patient outcome, including Candida eradication, will be documented for each patient by repeat culture.
- Serum concentrations (lab to be determined) and PK analysis of each echinocandin will be determined for each patient.
- Serum cidal titers will be measured against each of the Candida isolates for each agent at each time period. Median and geometric mean Peak and duration of cidal activity will then be determined and compared.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00839540
|United States, Michigan|
|Lansing, Michigan, United States, 48912|
|Principal Investigator:||Gary E Stein, Pharm.D.||Michigan State University|